Mabwell
Latest round
- Series A
Last raised
- Apr 2020
Total raised
- $279M
Investors
- 13
About Mabwell
, dba Mabwell is a biopharmaceutical company that engages in the development of macromolecular drugs such as monoclonal antibodies and long-acting recombinant proteins. The company's Chairman and CEO, Dr. Datao Liu, is a recipient of Special Government Allowances of the State Council. Mabwell has established manufacturing facilities in Taizhou, Shanghai, subsidiaries in Nanjing, Beijing, and other places in China, and a laboratory in San Diego, United States. In June 2020, the company was converted into a joint stock company. In January 2022, it was listed on the Shanghai Stock Exchange under the ticker "688062".64 apiece on the Hong Kong Exchanges and Clearing (HKEX) under the ticker "2493". Mabwell mainly focuses on developing and producing drugs internally for oncology, immunology, ophthalmology and orthopedics, having built a pipeline portfolio of both commercialized products and drug candidates. The company's main products include antibody-drug conjugates (ADCs), monoclonal antibodies (mAbs), fusion proteins and small molecules, and commercialized products for orthopedics, oncology and orthopedics. The company generates revenue from selling its commercialized drug products in China, primarily through third-party distributors who are responsible for on-selling and delivering the products generally to hospitals, medical institutions and pharmacies. After the IPO on Hong Kong Exchanges and Clearing in April 2026, Mabwell aims to advance the clinical development of its core product 9MW2821 for the treatment of multiple cancers toward commercialization, advance and expand other pipeline products focused on oncology and age-related diseases, and advance its commercialization network and business development efforts tailored to different markets.
Who invested in Mabwell
13 investors across 2 rounds
See all investors in Mabwell
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Mabwell
Who invested in Mabwell?
Mabwell has 13 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Mabwell raised?
Mabwell has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Mabwell last raise money?
Mabwell's most recent round on record is a Series A, in Apr 2020.
What does Mabwell do?
, dba Mabwell is a biopharmaceutical company that engages in the development of macromolecular drugs such as monoclonal antibodies and long-acting recombinant proteins.
Where is Mabwell headquartered?
Mabwell is headquartered in Shanghai, China.
Which VCs invest in companies like Mabwell?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Mabwell's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Mabwell? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.